Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-662rr Total loading time: 0.693 Render date: 2022-05-21T07:19:35.668Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

10 - Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

As with many first-generation antipsychotics (FGAs), zuclopenthixol and flupenthixol have no unique therapeutic benefit compared to other D2 antagonists, but have long-acting injectable (LAI) preparations available in certain parts of the world and a modest database of plasma level information. In addition to an LAI formulation, zuclopenthixol also has an injectable formulation (zuclopenthixol acetate) that provides therapeutic levels over several days, with a time to peak plasma levels (Tmax) of 24–48 hours [1].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 201 - 216
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lundbeck Canada Inc. (2016). Clopixol, Clopixol-Acuphase, Clopixol Depot product monograph. St. Laurent, Canada.
Jørgensen, A., Aaes-Jørgensen, T., Gravem, A., et al. (1985). Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl), 87, 364367.
Amdisen, A., Aaes-Jørgensen, T., Thomsen, N. J., et al. (1986). Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology (Berl), 90, 412416.
Szukalski, B., Lipska, B., Welbel, L., et al. (1986). Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology (Berl), 89, 428431.
Nyberg, S., Farde, L., Bartfai, A., et al. (1995). Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol, 10, 221227.
Balant-Gorgia, A. E., Balant, L. P., Gex-Fabry, M., et al. (1987). Stereoselective disposition of flupenthixol: influence on steady-state plasma concentrations in schizophrenic patients. Eur J Drug Metab Pharmacokinet, 12, 123128.
Reimold, M., Solbach, C., Noda, S., et al. (2007). Occupancy of dopamine D (1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupenthixol in comparison with risperidone and haloperidol. Psychopharmacology, 190, 241249.
Baumann, P., Kirchherr, H., Berney, P., et al. (2012). Flupenthixol: relevance of stereoselective therapeutic drug monitoring. Psychopharmacology (Berl), 221, 719720.
Davies, S. J., Westin, A. A., Castberg, I., et al. (2010). Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand, 122, 444453.
Balant-Gorgia, A. E., Eisele, R., Aeschlimann, J. M., et al. (1985). Plasma flupenthixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit, 7, 411414.
Walter, S., Bauer, S., Roots, I., et al. (1998). Quantification of the antipsychotics flupenthixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl, 720, 231237.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, http://doi.org/10.4088/JCP.4019cs13169.
Gex-Fabry, M., Balant-Gorgia, A. E., and Balant, L. P. (1997). Therapeutic drug monitoring databases for postmarketing surveillance of drug–drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit, 19, 110.
Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629651.
Linnet, K. and Wiborg, O. (1996). Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit, 18, 629634.
Balant-Gorgia, A. E. and Balant, L. (1987). Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet, 13, 6590.
Lundbeck Limited (2017). Depixol Tablets 3 mg – summary of product characteristics. St Albans, UK.
Wójcikowski, J., Pichard-Garcia, L., Maurel, P., et al. (2004). The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol, 14, 199208.
Paulzen, M., Haen, E., Hiemke, C., et al. (2017). Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol, 83, 16681675.
Norlén, M. and Allard, P. (1997). [3H]GBR 12935 binding in platelets: a possible association with cytochrome P-450IID6? Eur J Pharmacol, 332, 227230.
Kapur, S., Zipursky, R., Roy, P., et al. (1997). The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131, 148152.
Lundbeck Australia (2020). Fluanxol Depot and Fluanxol Concentrated Depot package insert. North Ryde, NSW, Australia.
Bailey, L. and Taylor, D. (2019). Estimating the optimal dose of flupenthixol decanoate in the maintenance treatment of schizophrenia – a systematic review of the literature. Psychopharmacology (Berl), 236, 30813092.
Jann, M. W., Ereshefsky, L., and Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet, 10, 315333.
Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl, 52, S1319.
Lambert, T. and Taylor, D. (2016). Pharmacology of antipsychotic long-acting injections. In Haddad, P., Lambert, T., and Lauriello, J., eds., Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press, pp. 3157.
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.
Bjørndal, F. and Aaes-Jørgensen, T. (1984). Serum concentration in acute paranoid psychosis treated with cis(Z)-clopenthixol. Nord Psykiatr Tidsskr 38, 229233.
Solgaard, T., Kistrup, K., Aaes-Jørgensen, T., et al. (1994). Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients: minimum effective dose and corresponding serum levels. Pharmacopsychiatry, 27, 119123.
Kistrup, K., Gerlach, J., Aaes-Jorgensen, T., et al. (1991). Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients: serum levels at the minimum effective dose. Psychopharmacology, 105, 4248.
Viala, A., Ba, B., Durand, A., et al. (1988). Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl), 94, 293297.
Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500505.
Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254264.
Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255261.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×